miltefosine has been researched along with Colorectal Neoplasms in 5 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 9.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 8.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 5.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "This study evaluated the biological and molecular functions of LRs in colorectal cancer (CRC) by using an LR-disrupting alkylphospholipid (APL) drug, miltefosine." | 4.02 | Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. ( Baek, JH; Choi, JH; Kim, JH; Lee, CJ; Lee, WJ; Nam, JS; Park, S; Park, SY; Park, ZY, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, SY | 1 |
| Kim, JH | 1 |
| Choi, JH | 1 |
| Lee, CJ | 1 |
| Lee, WJ | 1 |
| Park, S | 1 |
| Park, ZY | 1 |
| Baek, JH | 1 |
| Nam, JS | 1 |
| Planting, AS | 1 |
| Stoter, G | 2 |
| Verweij, J | 2 |
| Theischen, M | 1 |
| Bornfeld, N | 1 |
| Becher, R | 1 |
| Kellner, U | 1 |
| Wessing, A | 1 |
| Planting, A | 1 |
| van der Burg, M | 1 |
| Berger, MR | 1 |
| Richter, H | 1 |
| Seelig, MH | 1 |
| Eibl, H | 1 |
| Schmähl, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
3 trials available for miltefosine and Colorectal Neoplasms
| Article | Year |
|---|---|
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leuk | 1993 |
Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Electrooculography; Electroretinography | 1993 |
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore | 1992 |
2 other studies available for miltefosine and Colorectal Neoplasms
| Article | Year |
|---|---|
Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Me | 2021 |
New cytostatics--more activity and less toxicity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colorectal Neoplasms; Female; Male; Mammary Neoplasm | 1990 |